Since its inception in 2012, the Joseph Saveri Law Firm has quickly developed one of the most recognized antitrust and global competition law practices in the United States, recovering billions of dollars for classes of consumers and purchasers. Our top-notch, diverse set of attorneys have contributed to numerous Firm accolades rivaling those of larger, longer-tenured firms. We consistently serve in leadership roles in some of the nation’s most important antitrust cases.

To date, we have litigated cases across many industries, including banking and financial services, insurance, pharmaceuticals, computer hardware, computer software, travel and transportation, and consumer electronics. We represent individuals, consumers, small business owners, public officials, and heads of corporations that have been negatively affected by monopolistic business practices.

We are also active in⁠ – and have a winning record for⁠ – “no-poach” litigation involving illegal agreements among employers to not hire each other’s employees in order to suppress their employee’s mobility and earning potential.

Some of our most high-profile cases of antitrust and global competition

  • In re High-Tech Employees Antitrust Litigation: We served as Co-Lead Class Counsel for a class of over 60,000 employees of leading technology companies such as Google and Apple against their employers for their alleged agreements to restrict recruiting to suppress wages. Three Defendants agreed to settlements, now finalized, totaling $20 million. Following the Court’s denial of their motions for summary judgment, the remaining Defendants agreed to a settlement totaling $415 million, which has also received final approval.
  • In re Cipro Cases I and II: As Co-Lead Counsel, we are successfully representing a class of California consumers and insurers who brought antitrust claims against Bayer Corporation, Barr Laboratories, and other generic drug manufacturers, alleging that the companies paid drug manufacturers to delay the release of a Cipro alternative. In May 2015, The California Supreme Court ruled in Plaintiffs’ favor: a ground-breaking holding that these type of “pay-for-delay” arrangements were subject to antitrust scrutiny under California law and adopting a “structured” rule of reason that curtailed available defenses. The case settled in 2017 for $399 million: a record for this type of case.
  • In re Titanium Dioxide Antitrust Litigation: We served as Co-Lead Counsel to a class of direct purchasers of titanium dioxide who alleged that several primary suppliers engaged in an unlawful conspiracy to raise, maintain, or stabilize prices for titanium dioxide in the United States. This case produced a $163.5 million settlement.
  • In re Capacitors Price-Fixing Antitrust Litigation: We are currently Sole Lead Counsel in a class-action lawsuit alleging that global capacitor manufacturers conspired to fix prices, forcing direct purchasers to pay more. Capacitors are devices placed in electric circuits that temporarily store electrical charge, and nearly every electronic device manufactured today contains them. We seek damages relief for a Direct Purchasers Plaintiff Class for the unlawful overcharge on capacitors resulting from the Defendants’ alleged collusion. Class is certified and the trial is currently in progress. To date, Settlements reached with 16 of the original Defendants to the action total $433.5 million.
  • In re Lidoderm Antitrust Litigation: We served as End-Payors’ Interim Liaison Counsel in a class-action lawsuit brought by indirect purchasers of Lidoderm against Endo Pharmaceuticals, Teikoku, and Actavis Inc. Plaintiffs claim that Defendants entered into an illegal “reverse payment” agreement in which Endo provided nearly $100 million worth of branded Lidoderm and additional consideration to Actavis to keep generic lidocaine patches off the market. Plaintiffs allege that the agreement delayed generic competition and caused Plaintiffs to pay higher prices. The case settled in 2018 shortly before trial for $105 million.
  • In re Restasis (Cyclosporine Ophthalmic Emulsion) Antitrust Litigation: We are Interim Co-Lead Counsel for End-Payer Plaintiffs in an antitrust class action filed against Allergan, Inc., for an alleged scheme to delay generic competition to Allergan’s blockbuster Restasis drug (used primarily for chronic dry eyes treatment). The Firm sued on behalf of its client and named Class representative, Self-Insured Schools of California, which alleges that Allergan unlawfully extended its monopoly in the market for Restasis through a series of fraudulent and anticompetitive acts. Class certification motions are briefed, and a Court decision is pending. Trial is scheduled for late 2020.

Are you a victim of unfair competition? Have illegal agreements or other forms of collusive behavior hampered your employment or purchasing prospects? Perhaps you are concerned generally with the role of antitrust and global competition in our era of increasing business consolidation?

We encourage you to contact us about these or any other issues you are aware of that impact you, your colleagues, or your friends and family. We will answer your questions and evaluate your situation without charge, and any conversations will be kept confidential as provided by law. We are here for you when you need us.